Unmet needs, uncommon commitment: The shift toward investment in rare diseases

Join biotech leaders, emerging innovators, investors and patient advocacy group representatives for a candid, interactive and enlightening panel discussion about the evolving landscape in rare disease drug discovery and development. The panel discuss how approaches to rare disease research, drug development, commercialization and investment have changed in recent years, and why and how they’ve chosen to pursue leadership and innovation in rare diseases.

• Debra Miller – CureDuchenne
• Henri Termeer – Formerly Genzyme; Aura Biosciences
• Phil Vickers – Shire
• Flemming Ornskov – Shire